Compacted L-tryptophan Bulk Density Roller Compaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of L-tryptophan require high amounts of excipients and result in large dosage forms due to the low bulk density of conventional L-tryptophan, which affects bioavailability and volume.
Innovation Solution
A process using roller compaction to densify L-tryptophan without auxiliary excipients, increasing its bulk density and allowing for the preparation of compacted, high-density L-tryptophan with reduced excipient requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Volume of stationary object
If conventional L-tryptophan formulations are used, then the dosage forms are easier to manufacture with standard excipients, but the bulk density is low resulting in large volume and high excipient requirements
Solution Approach 1:
The invention changes the physical state of L-tryptophan from conventional low-density crystalline form to high-density compacted form through roller compaction, achieving bulk densities of 0.3-0.6 g/ml compared to conventional 0.1-0.2 g/ml. This parameter change in density directly reduces the volume and excipient requirements for pharmaceutical formulations.
2Reliability
If soft gelatin capsules with vegetable oils are used, then the bioavailability of L-tryptophan is improved, but the amount of excipients increases and the dosage form volume increases
Solution Approach 1:
The invention uses compacted L-tryptophan as an intermediary form that maintains the therapeutic benefits of oil-based formulations while eliminating the need for large amounts of vegetable oil excipients. The compacted form itself serves as the vehicle for improved bioavailability without requiring high volumes of auxiliary substances.
3Reliability
If high-dosage pharmaceutical forms are formulated, then the therapeutic effect is achieved, but the dosage form size becomes large and less patient-compliant
Solution Approach 1:
By changing the bulk density parameter of L-tryptophan through compaction, the invention enables high-dosage formulations (500-1000 mg and above) to be delivered in compact forms that maintain patient compliance. The increased density allows more active ingredient to be packed into a smaller volume without increasing the physical size of the dosage form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a significant increase in bulk density of L-tryptophan, reducing the volume and excipient needs in pharmaceutical compositions, enhancing bioavailability and patient compliance while maintaining chemical integrity.
Implementation Method 1
roller compaction of L-tryptophan
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention relates to a process for preparing substantially pure compacted L-tryptophan comprising roller compaction of L-tryptophan. It also relates to the compacted high-density L-tryptophan obtainable with such process, to the use of compacted L-tryptophan for preparing pharmaceutical compositions and to pharmaceutical compositions comprising compacted L-tryptophan as active ingredient. The process of the invention allows to remarkably increase the bulk density of L-tryptophan and, furthermore, by using compacted L-tryptophan, it is possible to considerably reduce the amount of excipients required to prepare pharmaceutical compositions comprising L-tryptophan as active ingredient.